M33.02 identifies juvenile dermatomyositis in a pediatric patient where documented muscle weakness or muscle enzyme elevation confirms myopathy as a concurrent manifestation of the inflammatory condition.
Verified May 8, 2026 · 5 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 10
- Region
- General
Documentation tips
What should appear in the chart to support M33.02.
Source · Editorial brief grounded in 5 cited references ↓
- Provider must explicitly document 'myopathy' or describe its clinical evidence (proximal muscle weakness, elevated CK/aldolase, abnormal EMG, or muscle biopsy) — the word 'myopathy' alone in the assessment is sufficient if supported by clinical findings.
- Record age of onset or explicitly label the condition 'juvenile' dermatomyositis; without this, the coder cannot distinguish M33.02 from M33.12 (adult/other dermatomyositis with myopathy).
- If multiple organ systems are involved (e.g., myopathy and respiratory compromise), code the primary manifestation driving the encounter first and add additional M33.0x codes as appropriate — or use M33.09 for the secondary involvement.
- When IVIG is planned or administered, ensure the diagnosis note documents the specific indication and disease activity to satisfy LCD medical-necessity criteria linked to M33.02.
- Document muscle enzyme lab values (CK, LDH, aldolase, AST) and imaging or biopsy results to support the myopathy specificity required at this code level.
Related CPT procedures
Procedure codes commonly billed with M33.02. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M33.02 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Assigning M33.02 for adult-onset dermatomyositis with myopathy — the correct code for adults is M33.12; M33.02 is reserved for juvenile (pediatric-onset) cases.
- Defaulting to M33.00 (organ involvement unspecified) when the record clearly documents muscle weakness or elevated enzymes — specificity is available and should be captured with M33.02.
- Confusing M33.02 (juvenile dermatomyositis with myopathy) with M33.03 (juvenile dermatomyositis without myopathy) — these are mutually exclusive; query the provider if the record is silent on muscle involvement.
- Failing to add secondary codes for separately documented and treated manifestations such as pulmonary fibrosis or myalgia, leaving clinical complexity undercoded.
Clinical context
Source · Editorial summary grounded in 5 cited references ↓
Use M33.02 when the patient has a confirmed juvenile dermatomyositis diagnosis (onset during childhood) and the provider has explicitly documented myopathy — typically evidenced by proximal muscle weakness, elevated creatine kinase or other muscle enzymes, abnormal EMG, or muscle biopsy findings consistent with inflammatory myopathy. This code sits under parent category M33.0 (Juvenile dermatomyositis) and is one of five subcodes distinguishing organ involvement: M33.00 (unspecified organ involvement), M33.01 (respiratory involvement), M33.02 (myopathy), M33.03 (without myopathy), and M33.09 (other organ involvement). Choose M33.02 only when myopathy is the documented systemic feature — not respiratory involvement or another organ system.
If the patient has adult-onset dermatomyositis with myopathy, the correct code is M33.12, not M33.02. Age of onset is the defining axis between M33.0x and M33.1x. If the record doesn't specify onset age or the provider hasn't clarified juvenile vs. adult classification, query the provider before coding. Using M33.00 (unspecified organ involvement) is appropriate only when the chart confirms juvenile dermatomyositis but lacks documentation of which organ systems are affected.
M33.02 appears on IVIG medical-necessity coverage lists (LCD L34007 and related MAC policies), so accurate use of this code supports prior authorization and medical necessity review for immunoglobulin therapy. Additional codes may be needed for concurrent manifestations such as pulmonary fibrosis (J84.10) or myalgia (M79.1) when separately documented and treated.
Sibling codes
Other billable codes under M33.0 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 5 cited references ↓
01What distinguishes M33.02 from M33.12?
02Can M33.02 and M33.01 be coded together for the same patient?
03Does M33.02 support IVIG medical necessity?
04What MS-DRG does M33.02 map to?
05When should M33.00 be used instead of M33.02?
06Is a muscle biopsy required to assign M33.02?
07Should additional codes be assigned alongside M33.02?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 — https://icd10cmtool.cdc.gov/
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M30-M36/M33-/M33.02
- 03outsourcestrategies.comhttps://www.outsourcestrategies.com/blog/code-dermatomyositis-common-rheumatology-disorder/
- 04nhpri.orghttps://www.nhpri.org/wp-content/uploads/2024/02/CMP_M_IVIG_Non-Onc.20240110.pdf
- 05aapc.comhttps://www.aapc.com/codes/icd-10-codes/M33.0
Mira AI Scribe
Mira's AI scribe captures the documented age of disease onset, presence and severity of proximal muscle weakness, muscle enzyme lab values (CK, aldolase, LDH), EMG findings, and any muscle biopsy results from the encounter note. This specificity locks in M33.02 over the less specific M33.00 and prevents downcoding on audit or IVIG prior-authorization review.
See how Mira captures M33.02 documentation